<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407183</url>
  </required_header>
  <id_info>
    <org_study_id>botox in neurogenic bladder</org_study_id>
    <nct_id>NCT03407183</nct_id>
  </id_info>
  <brief_title>The Efficacy of Botulinum Toxin in Spastic Neuropathic Bladder</brief_title>
  <official_title>The Efficacy of Botulinum Toxin in Spastic Neuropathic Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHMED FARAHAT HASSAN</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of botulinum toxin in spastic neurogenic bladder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurogenic detrusor overactivity (NDO) can result in lower and upper urinary tract&#xD;
      complications and eventually even in end-stage kidney failure. Since the driving force of&#xD;
      this clinical cascade is high bladder pressure, controlling intravesical pressure in NDO&#xD;
      patients improves both quality of life and life-expectancy in these patients. Botulinum toxin&#xD;
      A (BTX-A) has proven its efficacy in reducing intravesical pressure and in reducing&#xD;
      incontinence episodes. BTX-A also improves quality of life in patients with NDO. Both&#xD;
      onabotulinumtoxinA (Botox®, Allergan, Irvine, USA) and abobotulinumtoxinA (Dysport®, Ipsen,&#xD;
      Paris, France) have a level A recommendation for NDO-treatment. The recommended dose for&#xD;
      intradetrusor injections in NDO patients is 200 U of onabotulinumtoxinA or 500 U of&#xD;
      abobotulinumtoxinA. The drug is generally administered extratrigonal in the detrusor muscle,&#xD;
      via cystoscopic guided injection at 20 sites in 1 mL injections. Intradetrusor BTX-A&#xD;
      injections are safe, with mostly local complications such as urinary tract infection and high&#xD;
      post-void residual or retention. The effect of the toxin lasts for approximately 9 months.&#xD;
      Repeat injections can be performed without loss of efficacy. Different injection techniques,&#xD;
      novel ways of BTX-A administration, eliminating the need for injection or new BTX-A types&#xD;
      with better/longer response rates could change the field in the future.&#xD;
&#xD;
      Botulinum toxins are neurotoxins produced by the facultative anaerobe Clostridium botulinum&#xD;
      that block the release of acetylcholine into the synaptic gap of the neuromuscular junction.&#xD;
      Their injection near the nerves that supply the target organ selectively and temporarily&#xD;
      paralyzes the organ. In particular, the subtype botulinum-A toxin is widely used in neurology&#xD;
      to release spastic dystonia in adults and children . In urologic disorders, botulinum-A toxin&#xD;
      reliably diminishes external sphincter or detrusor overactivity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Efficacy of Botulinum Toxin in Spastic Neuropathic Bladder</measure>
    <time_frame>1 year</time_frame>
    <description>By improvement of symptoms and evaluation of urodynamic studies, Kidney function tests , abdominal ultrasound and urine analysis compared to preoperative results.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Spastic Neurogenic Bladder</condition>
  <arm_group>
    <arm_group_label>spastic neurogenic bladder</arm_group_label>
    <description>intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) in patients with spastic neurogenic bladder is 200 U of onabotulinumtoxinA once, then follow up after three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intradetrusor injection of botulinumtoxinA (Botox)</intervention_name>
    <description>intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.</description>
    <arm_group_label>spastic neurogenic bladder</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with spastic neurogenic bladder will be diagnosed clinically and urodynamically&#xD;
        with preoperative assessment through:&#xD;
&#xD;
        .History. .Examination. .Urine analysis. .Abdominal ultrasound (to assess upper urinary&#xD;
        tract and post micturation residual).&#xD;
&#xD;
        .Kidney function tests. .Urodynamic study. The patients will be re evaluated after 3 months&#xD;
        post botulinum toxin injection regarding to previous items.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -1- patients with spastic neurogenic bladder due to upper motor neuron lesion as (spinal&#xD;
        cord lesions ,multiple sclerosis ,strokes,parkinsonism...........).&#xD;
&#xD;
        2- patients with spastic neurogenic bladder diagnosed clinically and urodynamically.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1-patients with associated lower motor neuron lesions. 2-atonic bladder. 3-patients&#xD;
             with diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>AHMED FARAHAT, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AHMED FARAHAT, MASTER</last_name>
    <phone>01069569946</phone>
    <email>ahmedfarahat363@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mahmoud FARAHAT, MASTER</last_name>
    <phone>01069569946</phone>
    <email>ahmedfarahat363@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ahmed Farahat</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000 Sep;164(3 Pt 1):692-7.</citation>
    <PMID>10953127</PMID>
  </reference>
  <reference>
    <citation>Kirschner J, Berweck S, Mall V, Korinthenberg R, Heinen F. Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option. J Neurol. 2001 Apr;248 Suppl 1:28-30. Review.</citation>
    <PMID>11357236</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>AHMED FARAHAT HASSAN</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

